Biological therapeutic drugs, including nucleic acids, such as mRNAs, antisense oligonucleotide (ASO), and small interfering RNAs (siRNAs), and proteins, for example antibodies and peptides, have very different ADME features than traditional small chemical medications, which can directly impact on their therapeutic efficacy and adverse reactions. The session will contain several presentations from pharmaceutical industry and academics to provide updated information on ADME studies covering nucleic acid and protein drugs as well as their nanocarrier delivery systems.